LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions

By LabMedica International staff writers
Posted on 07 Feb 2024
Image: The DI-60 automated digital cell morphology analyzer developed by Sysmex in collaboration with CellaVision (Photo courtesy of Sysmex)
Image: The DI-60 automated digital cell morphology analyzer developed by Sysmex in collaboration with CellaVision (Photo courtesy of Sysmex)

Sysmex Corporation (Kobe, Japan) has entered into a strategic alliance agreement with CellaVision (Lund, Sweden) to advance hematology solutions. This collaboration aims to expand Sysmex's product range, including the development of cutting-edge cell morphology analyzers. Together, Sysmex and CellaVision will strive to improve the efficiency and standardization of testing workflows in hematology, enhance the accuracy of cell morphology classification, and provide valuable support in diagnostic processes.

The partnership between Sysmex and CellaVision has spanned 20 years, focusing on hematology, which involves the analysis of blood cells such as red and white blood cells in terms of their count, types, and sizes. This collaboration began in 2001 when Sysmex entered a sales alliance for CellaVision’s cell morphology analyzers. In 2013, Sysmex introduced the DI-60 Automated Digital Cell Morphology Analyzer, a product of its collaboration with CellaVision. This system, when integrated with Sysmex’s hematology analyzers, automates up to the cell morphology analysis stage, significantly streamlining and standardizing testing workflows in clinical laboratories worldwide.

The renewed partnership between the two companies aims to enhance their product offerings, particularly in next-generation cell morphology analyzers. They have agreed to extend their collaborative efforts to advance hematology solutions and maintain their agreement until 2038. Leveraging a stable, long-term collaborative framework, Sysmex plans to utilize its expertise in optimizing testing workflows in hematology, while CellaVision will contribute its advanced digital imaging and analysis technologies. These joint efforts are intended to further improve efficiency and standardization in testing workflows and increase clinical value by providing more precise cell morphology classification to aid in diagnoses.

“We are pleased to expand our alliance with CellaVision since 2013,” said Takashi Ono, Member of the Managing Board and Senior Executive Officer, Managing Director at Sysmex Corporation. “This alliance enables us to further enhance our leadership position in hematology worldwide. We will collaborate wider and deeper to increase value to our customers by portfolio expansion in digital cell morphology.”

"This alliance marks an important milestone in our joint mission to elevate healthcare and evolve microscopy together for a better healthcare journey,” said Simon Østergaard, President & CEO, CellaVision AB. “We are delighted to further strengthen our ties with Sysmex to continue the global adoption of advanced digital cell morphology solutions integrated with the leading cell counter offerings of Sysmex.”

Related Links:
Sysmex Corporation
CellaVision 

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
ESR Analyzer
TEST1 2.0

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more